Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
Background: Patients with heart failure (HF) and reduced ejection fraction will experience multiple hospitalizations for heart failure during the course of their disease. We assessed the …
Importance In 2 trials enrolling patients with heart failure (HF) across the spectrum of ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of …
Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …
Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical …
Importance Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …
Aims We examined the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients with heart failure (HF) with reduced ejection fraction …
KF Docherty, PS Jhund, I Anand, O Bengtsson… - Circulation, 2020 - Am Heart Assoc
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …
M Vaduganathan, BL Claggett, P Jhund… - Journal of the American …, 2023 - jacc.org
The sodium-glucose cotransporter-2 inhibitor dapagliflozin was recently demonstrated to reduce the combined risk of cardiovascular death or worsening heart failure (HF) in the …